Clinical trial leads to atezolizumab approval for advanced alveolar soft part sarcoma
A clinical trial has resulted in the first approval of a treatment for advanced alveolar soft part sarcoma (ASPS). The immunotherapy drug atezolizumab (Tecentriq) was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults and children 2 years and older with ASPS that has spread to other parts of the body or cannot be removed by surgery. ASPS is an extremely rare cancer that affects mostly adolescents and young adults.
Materials provided by NIH/National Cancer Institute. Note: Content may be edited for style and length.
Source link aaaaa